•
Dec 31, 2022

Natera Q4 2022 Earnings Report

Reported financial results for the fourth quarter and year ended December 31, 2022.

Key Takeaways

Natera reported a 25.6% increase in total revenues for Q4 2022, driven by a 28.2% increase in product revenues. The company processed approximately 559,700 tests and recognized revenue on approximately 519,200 tests.

Total revenues were $217.3 million in the fourth quarter of 2022, a 25.6% increase year-over-year.

Product revenues increased by 28.2% to $212.9 million in the fourth quarter of 2022.

Approximately 559,700 tests were processed in Q4 2022, with 543,900 tests accessioned in the laboratory.

Revenue was recognized on approximately 519,200 tests reported in Q4 2022.

Total Revenue
$217M
Previous year: $173M
+25.6%
EPS
-$1.37
Previous year: -$1.48
-7.4%
Tests Processed
559.7K
Previous year: 438.8K
+27.6%
Tests Accessioned
543.9K
Previous year: 424.2K
+28.2%
Total Tests Reported
519.2K
Previous year: 410.9K
+26.4%
Gross Profit
$90M
Previous year: $78.9M
+14.1%
Cash and Equivalents
$898M
Previous year: $915M
-1.8%
Free Cash Flow
-$93M
Previous year: -$108M
-13.7%
Total Assets
$898M
Previous year: $1.24B
-27.3%

Natera

Natera

Forward Guidance

Natera anticipates 2023 total revenue of $980 million to $1 billion; 2023 gross margin to be approximately 41% to 44% of revenues; selling, general and administrative costs to be approximately $510 million to $540 million; research and development costs to be $325 million to $345 million, and net cash consumption to be $300 million to $325 million.

Positive Outlook

  • 2023 total revenue of $980 million to $1 billion
  • 2023 gross margin to be approximately 41% to 44% of revenues
  • Selling, general and administrative costs to be approximately $510 million to $540 million
  • Research and development costs to be $325 million to $345 million
  • Net cash consumption to be $300 million to $325 million